Cresco acted as lead counsel to Taste Invest,the cornerstone investor of Novosanis, in the preparation, negotiation and closing of the strategic acquisition of Novasanis by OraSure Technologies, a NASDAQ publicly listed company active in de medical device industry.
Novosanis is an early commercial-stage producer and distributor of urine sample collection devices targeted primarily at the liquid biopsy, Sexually Transmitted Infection (STI) screening, and urological cancer markets. OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices
Yannick Verrycke led the Cresco team that advised Taste Invest in this strategic sale.
More information on the transaction can be found here.
For any further information or questions, please contact Yannick Verrycke.